ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
Income from Continuing Operations
ANI Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Income from Continuing Operations
$35.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
21%
|
CAGR 10-Years
27%
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is ANI Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
35.5m
USD
Based on the financial report for Mar 31, 2024, ANI Pharmaceuticals Inc's Income from Continuing Operations amounts to 35.5m USD.
What is ANI Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
27%